Advanced search
Publication Cover
Current Opinion on Therapeutic Patents Volume 2, 1992 - Issue 4
Journal homepage
9
Views
2
CrossRef citations to date
0
Altmetric
Biotechnology & Immunology

Overview: Strategies for the Prevention of Graft Rejection

Johan Van den Bogaerde Department of Internal Medicine, University of Pretoria, Pretoria 2000, South Africa
Pages 463-476 | Published online: 02 Mar 2011

References to Primary Literature

  • Friend PJ, Lim S, Smith M, Jameson NV, Rolles K, O'Grady J, Williams R, Calne RY Liver transplantation in the Cambridge/King's College Hospital series - the first 400 patients. Transplant. Proc. 1989.
  • Borel JF, Feurer C, Gubler HU, Stahelin H Biological effects of cyclosporin A: A new antilymphocytic agent. Agents Actions 1976 6 468–475 Introduction of cyclosporin A as an immunosuppressive.
  • Calne RY, Rolles K, White DJ, Thiru S, Evans DB, McMaster P, Dunn DC, Craddock GN, Henderson RG, Aziz S, Lewis P Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases, and 2 livers. Lancet 1979 2 1033–1036.
  • Schwartz RH Acquisition of immunologic self-tolerance. Cell 1989 57 1073–1081.
  • Blackman M, Kappler J, Marrack P The role of the T cell receptor in positive and negative selection of developing T cells. Science 1990 248 1335–1341.
  • Calne RY, White HJ, Yoffa DE, Maginn RR, Binns RM, Samuel JR, Molina VP Observations of orthotopic liver transplantation in the pig. Br. Med. J. 1967 2 478–480.
  • White DJ, Calne RY, Plumb A Mode of action of cyclosporin A: A new immunosuppressive agent. Transplant. Proc. 1979 11 855–859.
  • Calne RY, White DJ, Thiru S, Evans DB, McMaster P, Dunn DC, Craddock GN, Rolles K Cyclosporin A in clinical kidney grafting from cadaver donors. Proc. Eur. Dial. Transplant. Assoc. 1979 16 305–309.
  • Warty V, Diven W, Cadoff E, Todo S, Starzl T, Sanghvi A FK506: A novel immunosuppressive agent Characteristics of binding and uptake by human lymphocytes. Transplantation 1988 46 453–455.
  • Ricordi C, Zeng YJ, Alejandro R, Tzakis A, Venkataramanan R, Fung J, Bereiter D, Mintz DH, Starzl TE In vivo effect of FK506 on human pancreatic islets. Transplantation 1991 52 519–1991.
  • Murase N, Kim DG, Todo S, Cramer DV, Fung J, Starzl TE FK506 suppression of heart and liver allograft rejection. II. The induction of graft acceptance in rats. Transplantation 1990 50 739–744.
  • Collier DS, Calne R, Thiru S, Friend PJ, Lim S, White DJ, Kohno H, Levickis J FK506 in experimental renal allografts. Transplant. Proc. 1987 19 3975–3977.
  • Gorer PA The antigenic basis of tumour transplantation. J. Path. Bact. 1938 47 597–603 The first article to describe the MHC.
  • Klein J The natural history of the major histocompatibility complex. A Wiley Inter-science publication John Wiley and Sons New York 1986.
  • Morris RE Rapamycin: FK506's fraternal twin or distant cousin?. Immunol. Today 1991 12 137–140 Excellent review of these two drugs.
  • Hess AD, Tutschka PJ, Santos GW Effect of cyclosporin A on human lymphocyte responses in vitro. III. CsA inhibits the production of T lymphocyte growth factors in secondary mixed lymphocyte responses but does not inhibit the response of primed lymphocytes to TCGF. J. Immunol. 1982 128 355–359.
  • Tilney NL, Strom TB, Chemical manipulation of the immune response, Organ transplantation and replacement Cerilli G.J. J. B. Lippincot Company Philadelphia 1988 118–136.
  • Dumont FJ, Melino MR, Struch MJ, Koprak SL, Fischer PA, Sigal NH The immunosuppressive macrolides FK-506 and rapamycin act as reciprocal antagonists in murine T cells. J. Immunol. 1990 144 1418–1524.
  • Reyes J, Gayowski T, Fung J, Todo S, Alessiani M, Starzl TE Expression dysphasia possibly related to FK506 in two liver transplant recipients. Transplantation 1990 50 1043–1045.
  • Elmagd Abu K, Fung JJ, Alessiani M, Jain A, Venkataramanan R, Warty VS, Takaya S, Todo S, Shannon WD, Starzl TE The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver. Transplantation 1991 52 71–77.
  • Calne RY, Collier DS, Lim S, Pollard SG, Samaan A, White DJ, Thiru S Rapamycin for immunosuppression in organ allografting [letter] [see comments]. Lancet 1989 2.
  • Collier DS, Calne R, Thiru S, Lim S, Pollard SG, Barron P, Da CM, White DJ Rapamycin in experimental renal allografts in dogs and pigs. Transplant. Proc. 1990 22 1674–1675.
  • Morris RE, Meiser BM, Wu J, Shorthouse R, Wang J Use of rapamycin for the suppression of alloimmune reactions in vivo: Schedule dependence, tolerance induction, synergy with cyclosporine and FK506, and effect on host-versus-graft and graft-versus-host reactions. Transplant. Proc. 1991.
  • Lang K, Schmid FX, Fischer G Catalysis of protein folding by prolyl isomerase. Nature 1987 329 268–270.
  • Bierer BE, Schreiber SL, Burakoff SJ Mechanisms of immunosupression by FK506. Preservation of T cell transmembrane signal transduction. Transplantation 1990 49 1168–1170.
  • Kiefhaber T, Quass R, Hahn U, Schmid FX Folding of ribonuclease T1. I. Existence of multiple unfolded states created by proline isomerization. Biochemistry 1990 29 3053–5061.
  • Kiefhaber T, Quaas R, Hahn U, Schmid FX Folding of ribonuclease T1. 2. Kinetic models for the folding and unfolding reactions. Biochemistry 1990 29 3061–3070.
  • Bierer BE, Mentzer SJ, Greenstein JL, Burakoff SJ The role of functional cell surface antigens in T cell activation. Year Immunol. 1986 2 39–59.
  • Bierer BE, Schreiber SL, Burakoff SJ Mechanisms of immunosuppression by FK 506. Preservation of T cell transmembrane signal transduction. Transplantation 1990 49 1168–1170.
  • Bierer BE, Mattila PS, Standaert RF, Herzenberg LA, Burakoff SJ, Crabtree G, Schreiber SL Two distinct signal transmission pathways in T lymphocytes are inhibited by complexes formed between an immunophilin and either FK506 or rapamycin. Proc. Natl. Acad. Sci. USA 1990 87 9231–9235.
  • Shaw JP, Utz PJ, Durand DB, Toole JJ, Emmel EA, Crabtree GR Identification of a putative regulator of early T cell activation genes. Science 1988 241 202–205.
  • Emmel EA, Verweij CL, Durand DB, Higgins KM, Lacy E, Crabtree GR Cyclosporin A specifically inhibits function of nuclear proteins involved in T cell activation. Science 1989 246 1617–1620.
  • Moore JM, Peattie DA, Fitzgibbon MJ, Thomson JA Solution structure of the major binding protein for the immunosuppressant FK506 [see comments]. Nature 1991 351 248–250.
  • Michnick SW, Rosen MK, Wandless TJ, Karplus M, Schreiber SL Solution structure of FKBP, a rotamase enzyme and receptor for FK506 and rapamycin. Science 1991 252 836–839.
  • Ringe D Immunosuppression. Binding by design [news; comment]. Nature 1991 351 185–186 Excellent review of mechanism of action of new immuno-suppresive drugs.
  • Bierer BE, Somers PK, Wandless TJ, Burakoff SJ, Schreiber SL Probing immunosuppressant action with a nonnatural immunophilin ligand. Science 1990 250 556–559.
  • Sigal NH, Dumont F, Durette P, Siekierka JJ, Peterson L, Rich DH, Dunlap BE, Staruch MJ, Melino MR, Koprak SJ, Is cyclophilin involved in the immunosuppressive and nephrotoxic mechanism of action of cyclosporin A?. J. Exp. Med. 1991 173 619–628.
  • Tocci MJ, Matkovich DA, Collier KA, Kwok P, Umont F, Lin S, Degudicibus S, Siekierka JJ, Chin J, Hutchinson NI The immunosupressant FK506 selectively inhibits expression of early T cell activation genes. J. Immunol. 1989 143 718–726 Important reference about the action of immunophilin binding drugs.
  • Dumont FJ, Staruch MJ, Koprak SL, Melino MR, Sigal NH Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK-506 and rapamycin. J. Immunol. 1990 144 251–258.
  • Siekierka JJ, Struch MJ, Hung SH, Sigal NH FK-506, a potent novel immunosuppressive agent, binds to a cytosolic protein which is distinct from the cyclosporin A-binding protein, cyclophilin. J. Immunol. 1989 143 1580–1583.
  • Monaco AP, Biological immunosuppression: Polyclonal antilymphocyte sera, monoclonal antibody and donor-specific antigen, Organ transplantation and replacement Cerilli G.J. J. B. Lippincot Company Philadelphia 1988 83–117.
  • Maki T, Gottschalk R, Wood ML Specific unresponsiveness to skin allografts in antilymphocyte serum treatment in mice. J. Immunol. 1982 127 1433–1438.
  • Kohler G, Milstein C Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975 256 495–497.
  • Knapp W, Rieber P, Dorken B, Schmidt RE, Stein H DBA Towards a better definition of human leukocyte surface molecules. Immunol. Today 1989 10 253–258.
  • Bagshawe KD Antibody directed enzymes revive anti-cancer prodrugs concept. Br. J. Cancer 1987 56 531–532.
  • Norman DJ, Leone MR The role of OKT3 in clinical transplantation. Pediatr. Nephrol. 1991 5 130–136.
  • Welter HF, Illner WD, Schleibner S, Abendroth D, Hancke E, Groh J, Land W Pilot study on induction treatment with high-dose OKT3: Preliminary observations in kidney transplantation. Transplant. Proc. 1990 22.
  • Wong JT, Eylath AA, Ghobrial I, Colvin RB The mechanism of anti-CD3 monoclonal antibodies. Mediation of cytolysis by inter-T cell bridging. Transplantation 1990 50 683–689.
  • Pulpon LA, Dominguez P, Chafer M, Segovia J, Crespo MG, Pradas G, Burgos R, Figuera D Induction immunosuppression with OKT3 monoclonal antibody in cardiac transplant recipients. Transplant. Proc. 1990 22.
  • Friend PJ, Waldmann H, Hale G, Cobbold S, Rebello P, Thiru S, Jameson NV, Johnston PS, Calne RY Reversal of allograft rejection using the monoclonal antibody, Campath-1G. Transplant. Proc. 1991 23 2253–2254.
  • Waldman H, Polliak A, Hale G, Or R, Cividalli G, Weiss L, Weshler Z, Samuel S, Manor D, Brautbar C, Elimination of graft-versus-host disease by in vitro depletion of alloreactive lymphocytes with a monoclonal rat anti-human lymphocytes with a monoclonal rat anti-human lymphocyte antibody (CAMPATH-1). Lancet 1984 2 483–486.
  • Apperley JF, Jones L, Hale G, Waldman H, Hows J, Rombos Y, Tsatalas C, Marcus RE, Goolden AW, Gordon SmithE, Bone marrow transplantation for patients with chronic myeloid leukaemia: T-cell depletion with Campath-1 reduces the incidence of graft-versus-host disease but may increase the risk of leukaemic relapse. Bone Marrow Transplant 1986 1 53–66.
  • Hale G, Dyer MJ, Clark MR, Phillips JM, Marcus R, Riechmann L, Winter G, Waldmann H Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H. Lancet 1988 2 1394–1399.
  • Antin JH, Bierer BE, Smith BR, Guina EC, Provost MM, Ferrara J, Macklis RM, Tarbell NJ, Blythman H, Bouloux C, Depletion of bone marrow T-lympho-cytes with an anti-CD5 monoclonal immunotoxin (ST-1 immunotoxin): Effective prophylaxis for graft-versus-host disease. Progress in Clinical & Biological Research 1990 333 207–215.
  • Benjamin RJ, Cobbold SP, Clark MR, Waldmann H Tolerance to rat monoclonal antibodies. Implications for serotherapy. J. Exp. Med. 1986 163 1539–1552.
  • Qin S, Cobbold S, Tighe H, Benjamin R, Waldmann H CD4 monoclonal antibody pairs for immunosuppression and tolerance induction. Eur. J. Immunol. 1987 17 1159–1165.
  • Cobbold SP, Jayasuriya A, Nash A, Prospero TD, Waldmann H Therapy with monoclonal antibodies by elimination of T-cell subsets in vivo. Nature 1984 312 548–551.
  • Cobbold S, Martin G, Waldmann H Monoclonal antibodies for the prevention of graft-versus-host disease and marrow graft rejection. The depletion of T cell subsets in vitro and in vitro. Transplantation 1986 42 239–247.
  • Cobbold S, Waldmann H Skin allograft rejection by L3/T4+ and Lyt-2+ T cell subsets [published erratum appears in Transplantation 1986 Sep; 42(3):332]. Transplantation 1986 41 634–639.
  • Woodcock J, Wofsy D, Eriksson E, Scott JH, Seaman WE Rejection of skin grafts and generation of cytotoxic T cells by mice depleted of L3T4+ cells. Transplantation 1986 42 636–642.
  • Herbert J, Roser B Strategies of monoclonal antibody therapy that induce permanent tolerance of organ transplants. Transplantation 1988.
  • Burkhardt K, Charlton B, Mandel TE An increase in the survival of murine H-2-mismatched cultured fetal pancreas allografts using depleting or nondepleting anti-CD4 monoclonal antibodies, and a further increase with the addition of cyclosporine. Transplantation 1989 47 771–775.
  • Queen C, Schneider WP, Selick HE, Payne PW, Landolfi NF, Duncan JF, Avdalovic NM, Levitt M, Junghans RP, Waldmann TA A humanized antibody that binds to the interleukin 2 receptor. Proc. Natl. Acad. Sci. USA 1989 86 10029–10033.
  • Chaudhary VK, Queen C, Junghans RP, Waldman TA, Fitz GeraldDJ, Pastan I A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin. Nature 1989 339 394–397.
  • Waldman H Manipulation of T-cell responses with monoclonal antibodies. Annu Rev. Immunol. 1989 7 407–444 Good review about monoclonal antibodies.
  • Winter G, Milstein C Man-made antibodies. Nature 1991 349 293–299 Excellent review about the molecular biological manipulation of monoclonal antibodies.
  • Neuberger MS, Williams GT, Fox RO Recombinant antibodies possessing novel effector functions. Nature 1984 312 604–608.
  • LoBuglio AF, Wheeler GT, Trang J, Haynes A, Rogers K, Harvey EB, Sun L, Ghrayeb J, Khazaeli MB Mouse/human chimeric monoclonal antibody in man: Kinetics and immune response. Proc. Natl. Acad. Sci. USA 1989 86 4220–4224.
  • Bruggemann M, Winter G, Waldmann H, Neuberger MS The immunogenicity of chimeric antibodies. J. Exp. Med. 1989 170 2153–2157.
  • Jones PT, Dear PH, Foote J, Neuberger MS, Winter G Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 1986 321 522–525.
  • Verhoeyen M, Milstein C, Winter G Reshaping human antibodies: Grafting an antilysozyme activity. Science 1988 239 1534–1536.
  • Milstein C, Cuello AC Hybrid hybridomas and their use in immunohistochemistry. Nature 1983 305 537–540.
  • Lanzavecchia A, Scheidegger D The use of hybrid hybridomas to target human cytotoxic T lymphocytes. Eur. J. Immunol. 1987 17 105–111.
  • Clark MR, Waldmann H T-cell killing of target cells induced by hybrid antibodies: Comparison of two bispecific monoclonal antibodies. J. Natl. Cancer Inst. 1987 79 1393–1401.
  • Orlandi R, Gussow DH, Jones PT, Winter G Cloning immunoglobulin variable domains for expression by the polymerase chain reaction. Proc. Natl. Acad. Sci. USA 1989 86 3833–3837.
  • Marks JD, Tristem M, Karpas A, Winter G Oligonucleotide primers for polymerase chain reaction amplification of human immunoglobulin variable genes and design of family-specific oligonucleotide probes. Eur. J. Immunol. 1991 21 985–991.
  • Orlandi R, Gussow DH, Jones PT, Winter G Cloning immunoglobulin variable domains for expressing by the polymerase chain reaction. Proc. Natl. Acad. Sci. USA 1989 86 3833–3837.
  • Larrick JW, Coloma MJ, Del VJ, Fernandez ME, Fry KE, Gavilondo CJ Immunoglobulin V regions of a bactericidal anti-Neisseria meningitidis outer membrane protein monoclonal antibody. Scand. J. Immunol. 1990 32 121–128.
  • Huse WD, Sastry L, Iverson SA, Kang AS, Alting MM, Burton DR, Benkovic SJ, Lerner RA Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda [see comments]. Science 1989 246 1275–1281.
  • Clackson T, Hoogenboom HR, Griffiths AD, Winter G Making antibody fragments using phage display libraries. Nature 1991 352 624–628.
  • Hoogenboom HR, Griffiths AD, Johnson KS, Chiswell DJ, Hudson P, Winter G Multi-subunit proteins on the surface of filamentous phage: Methodologies for displaying antibody (Fab) heavy and light chains. Nucl. Acids Res. 1991 19 4133–4137.
  • McCafferty J, Griffiths AD, Winter G, Chiswell DJ Phage antibodies: Filamentous phage displaying antibody variable domains. Nature 1990 348 552–554.
  • Skerra A, Dreher ML, Winter G Filter screening of antibody Fab fragments secreted from individual bacterial colonies: Specific detection of antigen binding with a two-membrane system. Anal. Biochem. 1991 196 151–155.
  • Gussow D, Ward ES, Griffiths AD, Jones PT, Winter G Generating binding activities from Escherichia coli by expression of a repertoire of immunoglobulin variable domains. Cold Spring Harbor Symposia on Quantitative Biology 1989 1 265–272.
  • Berek C, Milstein C The dynamic nature of the antibody repertoire. Immunol. Rev. 1988 105 5–26.
  • Mariuzza RA, Winter G Secretion of a homodimeric V alpha C kappa T-cell receptor-immunoglobulin chimeric protein. J. Biol. Chemistry 1989 264 7310–7316.
  • Adelstein S, Pritchard BH, Anderson TA, Crosbie J, Gammon G, Loblay RH, Basten A, Goodnow CC Induction of self-tolerance T cells but not B cells of transgenic mice expressing little self antigen. Science 1991 251 1223–1225.
  • Matzinger P, Bevan MJ Hypothesis: Why do so many lymphocytes respond to major histocompatibility antigens?. Cell Immunol. 1977 29 1–5.
  • Blackman MA, Finkel TH, Kappler J, Cambier J, Marrack P Altered antigen receptor signalling in anergic T cells from self-tolerant T-cell receptor beta-chain transgenic mice. Proc. Natl. Acad. Sci. USA 1991 88 6682–6686.
  • Bjorkman PJ, Saper MA, Samraoui B, Bennett WS, Strominger JL, Wiley DC Structure of the human class I histocompatibility antigen, HLA-A2. Nature 1987 329 506–512.
  • Bjorkman PJ, Saper MA, Smaraoui B, Bennett WS, Strominger JL, Wiley DC The foreign antigen binding site and T cell recognition regions of class I histocompatibility antigens. Nature 1987 329 512–518 First description of the crystallographic nature of MHC class I.
  • Grey HM, Sette A, Buus S Structural characteristics of peptides required for their interaction with IAd. Ann. NY Acad. Sci. 1988 546 72–79.
  • Chen BP, Parham P Direct binding of influenza peptides to class I HLA molecules. Nature 1989 337 743–745.
  • Buus S, Sette A, Colon SM, Jenis DM, Grey HM Isolation and characterization of antigen-Ia complexes involved in T cell recognition. Cell 1986 47 1071–1077.
  • Lechler RI, Batchelor JR Restoration of immunogenicity to passenger cell-depleted kidney allografts by the addition of donor strain dendritic cells. J. Exp. Med. 1982 155 31–41.
  • Lechler RI, Batchelor JR Immunogenicity of retransplanted rat kidney allografts. Effect of inducing chimerism in the first recipient and quantitative studies on immunosuppression of the second recipient. J. Exp. Med. 1982 156 1835–1841.
  • Adorini L, Muller S, Cardinaux F, Lehmann PV, Falcioni F, Nagy ZA In vivo competition between self peptides and foreign antigens in T-cell activation. Nature 1988 334 623–1988.
  • Adorini L, Appella E, Doria G, Nagy SA Mechanisms influencing the immunodominance of T cell determinants. J. Exp. Med. 1988 168 2091–2104.
  • Babbitt BP, Allen PM, Matsueda G, Haber E, Unanue ER Binding of immunogenic peptides to Ia histocompatibility molecules. Nature 1985 317 359–361.
  • Werdelin O, Mouritsen S, Petersen BL, Sette A, Buus S Facts on the fragmentation of antigens in presenting cells, on the association of antigen fragments with MHC molecules in cell-free systems, and speculation on the cell biology of antigen processing. Immunol. Rev. 1988 106 181–193.
  • Matzinger P, Zamoyska R, Waldman H Self tolerance is H-2-restricted. Nature 1984 308 738–741.
  • Hughes AL, Nei M Pattern of nucleotide substitution at major histocompatibility complex class I loci reveals overdominant selection. Nature 1988 335 167–170.
  • Auchincloss HJ Xenogeneic transplantation. A review. Transplantation 1988 46 1–20.
  • Reemtsma K, McCracken BH, Schlegel JY Renal heterotransplantation in man. Ann. Surg. 1964 160.
  • Starzl TE, Marchioro TL, Porter GN Renal heterotransplantation from baboon to man: Experiences with 6 cases. Transplantation 1964 2 752–776.
  • Caplan AL Ethical issues raised by research involving xenografts. J. Am. Med. Assoc. 1985 254 3339–3343.
  • Calne RY Organ transplantation between widely dispartate species. Transplant Proc. 1970 2 550–559.
  • Van den Bogaerde J, Aspinall R, Wang MW, Cary N, Lim S, Wright L, White D Induction of long-term survival of hamster heart xenografts in rats. Transplantation 1991 52 15–20.
  • Perper RJ, Najarian JS Experimental renal heterotransplantation. I. In widely divergent species. Transplantation 1966 4 377–388.
  • Kissmeyer NJ, Olsen S, Petersen VP, Fjeldborg O Hyperacute rejection of kidney allografts, associated with pre-existing humoral antibodies against donor cells. Lancet 1966 2 662–665.
  • Paul L, Mechanism of humoral xenograft rejection, Xenotransplantation: The transplantation of organs and tissues between species Cooper DKC Kemp E. Reemtsma K. White DJG Springer-Verlag Berlin 1991 47–68.
  • Bailey L, Nehlsen-Cannarella S, Conception W, Jolley W Baboon-to-human cardiac xenotransplantation in a neonate. J. Am. Med. Assoc. 1985 245 3321–3334.
  • Cochrane CG, Muller EH, Aikin BS Depletion of plasma complement in vivo by a protein of cobra venom: Its effect on various immunologic reactions. J. Immunol. 1970 105 55–69.
  • Valdivia LA, Monden M, Gotoh M, Nakano Y, Tono T, Mori T Evidence that deoxyspergualin prevents sensitization and first-set cardiac xenograft rejection in rats by suppression of antibody formation. Transplantation 1990 50 132–136.
  • Van den Bogaerde J, White D, Immunosuppression in xenotransplantation, Xenotransplantation: The transplantation of organs and tissues between species Cooper DKC Kemp E. Reemtsma K. White DJG Springer-Verlag Berlin 1991 161–178.
  • Platt J, Bach F, Mechanism of tissue injury in hyperacute xenograft rejection, Xenotransplantation: The transplantation of organs and tissues between species Cooper DKC Kemp E. Reemtsma K. White DJG Springer-Verlag Berlin 1991 69–81.
  • Johnston P, Wang M, Lim S, Wright L, White D Hyperacute xenograft rejection takes place in the complete absence of antibodies but requires the presence of functional complement. Transplant. Proc. 1991 23 877–880.
  • Miyagawa S, Hirose H, Shirakura R, Naka Y, Kawashima Y, Seya T, Matsumo M, Uenaka A, Kitamura H The mechanism of discordant xenograft rejection. Transplantation 1988 46 825–830.
  • Schilling A, Land W, Pratschke E, Pielsticker K, Brendel W Dominant role of complement in the hyperacute xenograft rejection reaction. Surg. Gynecol. Obstet. 1976 142 29–32.
  • Atkinson J, Farries T Separation from self from non-self in the complement system. Immunol. Today 1987 8 212–215 Good review of complement inhibiting molecules.
  • Seya T, Farries T, Nickells M, Atkinson JP Additional forms of human decay-accelerating factor (DAF). J. Immunol. 1987 139 1260–1267.
  • Rooney IA, Davies A, Griffiths D, Williams JD, Davies M, Meri S, Lachmann PJ, Morgan BP The complement-inhibiting protein, protectin (CD59 antigen), is present and functionally active on glomerular epithelial cells. Clin. Exp. Immunol. 1991 83 251–256.
  • Meri S, Morgan BP, Davies A, Daniels RH, Olavesen MG, Waldmann H, Lachmann PJ Human protectin (CD59), an 18,000–20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. Immunology 1990 7 1–9.
  • Platt JL, Vercellotti GM, Dalmasso AP, Matas AJ, Bolman RM, Najarian JS, Bach FH Transplantation of discordant xenografts: A review in progress. Immunol. Today 1990 11 450–456.
  • Dalmasso AP, Vercellotti GM, Platt JL, Bach FH Inhibition of complement-mediated endothelial cell cytotoxicity by decay-accelerating factor. Potential for prevention of xenograft hyperacute rejection. Transplantation 1991 52 530–533.

References to Patent Literature

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.